+++ 821.149 Press releases +++ 33.966 Newsrooms +++ 6.000 Media +++

Open-source Analysis Tool enables Rapid Annotation of Metagenomes

The new metagenomic RAST server is designed specifically for use with data generated by 454 Sequencing(TM) systems

(PresseBox) (Mannheim, ) The study of microbial communities from environmental samples, known as metagenomics, has been propelled forward by technological advancements in high-throughput, low-cost sequencing such as 454's Genome Sequencer FLX System. With the recent use of sequencing approaches for metagenomic analysis, the major research challenges have shifted from generating to analyzing data. To resolve these analysis bottlenecks, a team of researchers from Argonne National Laboratory, The University of Chicago, and San Diego State University have developed an open source system for automated processing of metagenomic sequence data. The resource, designed specifically for data files generated by the 454 Sequencing platform, generates phylogenetic and functional summaries of the genomes by comparing the sequence against protein and nucleotide databases.

The metagenomics-RAST server, available at http://metagenomics.nmpdr.org/..., is based on the SEED framework for comparative genomics. Researchers can upload data sets directly in the file format generated by the GS FLX instrument, either as raw reads or assembled contigs. "We built this analysis tool with specific consideration for 454 Sequencing data sets," explained Rob Edwards, the project lead. "Only the long sequence reads from the GS FLX System ensure the specificity needed to compare data against DNA or protein databases for functional annotation, making it the platform of choice for metagenomic analysis."

Metagenomes uploaded to the high-throughput pipeline are compared against a variety of known sequence databases, including rRNA and mitochondrial databases, and are screened for protein encoding genes. The tool provides the data types needed for phylogenetic comparisons, functional annotations, binning of sequences, phylogenomic profiling, and metabolic reconstructions.

"We are excited to see the development of this new online annotation tool," said Ulrich Schwoerer, Head of Global Marketing 454 Life Science, a Roche company. "As we continue to improve our sequencing technology with higher throughput and longer reads, we support efforts to build collaborative networks for sharing and analyzing data within the metagenomic research community."

The study titled "The metagenomic RAST server- a public resource for the automatic phylogenetic and functional analysis of metagenomes," appears in the journal BMC Bioinformatics.

454 Life Sciences, a center of excellence of Roche Applied Science, develops and commercializes the innovative 454 Sequencing system for ultra-high-throughput DNA sequencing. Specific applications include de novo sequencing and re-sequencing of genomes, metagenomics, RNA analysis, and targeted sequencing of DNA regions of interest. The hallmarks of the 454 Sequencing system are its simple, unbiased sample preparation and long, highly accurate sequence reads, including paired-end reads. The technology of the 454 Sequencing system has enabled hundreds of peer-reviewed studies in diverse research fields, such as cancer and infectious disease research, drug discovery, marine biology, anthropology, paleontology and many more.

About Roche Diagnostics Deutschland GmbH

Headquartered in Basel, Switzerland, Roche is one of the world's leading research-focused healthcare groups in the fields of pharmaceuticals and diagnostics. As the world's biggest biotech company and an innovator of products and services for the early detection, prevention, diagnosis and treatment of diseases, the Group contributes on a broad range of fronts to improving people's health and quality of life. Roche is the world leader in in-vitro diagnostics and drugs for cancer and transplantation, and is a market leader in virology. It is also active in other major therapeutic areas such as autoimmune diseases, inflammatory and metabolic disorders and diseases of the central nervous system. In 2007 sales by the Pharmaceuticals Division totalled 36.8 billion Swiss francs, and the Diagnostics Division posted sales of 9.3 billion francs. Roche has R&D agreements and strategic alliances with numerous partners, including majority ownership interests in Genentech and Chugai, and invested over 8 billion Swiss francs in R&D in 2007. Worldwide, the Group employs about 80,000 people. Additional information is available on the Internet at www.roche.com.

Press releases you might also be interested in

Subscribe for news

The subscribtion service of the PresseBox informs you about press information of a certain topic by your choice at a choosen time. Please enter your email address to receive the email with the press releases.

An error occurred!

Thank you! You will receive a confirmation email within a few minutes.